These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11222559)

  • 1. Antimicrobial activity of fluoroquinolone photodegradation products determined by parallel-line bioassay and high performance liquid chromatography.
    Sunderland J; Tobin CM; Hedges AJ; MacGowan AP; White LO
    J Antimicrob Chemother; 2001 Mar; 47(3):271-5. PubMed ID: 11222559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins.
    Brisse S; Milatovic D; Fluit AC; Verhoef J; Martin N; Scheuring S; Köhrer K; Schmitz FJ
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2051-5. PubMed ID: 10428935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodegradation of fluoroquinolones in surface water and antimicrobial activity of the photoproducts.
    Sturini M; Speltini A; Maraschi F; Pretali L; Profumo A; Fasani E; Albini A; Migliavacca R; Nucleo E
    Water Res; 2012 Nov; 46(17):5575-5582. PubMed ID: 22901305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.
    Rodríguez JC; Ruiz M; Climent A; Royo G
    Int J Antimicrob Agents; 2001 Mar; 17(3):229-31. PubMed ID: 11282270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
    Firsov AA; Lubenko IY; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
    J Antimicrob Chemother; 2000 Nov; 46(5):725-32. PubMed ID: 11062191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photodegradation of some quinolones used as antimicrobial therapeutics.
    Tiefenbacher EM; Haen E; Przybilla B; Kurz H
    J Pharm Sci; 1994 Apr; 83(4):463-7. PubMed ID: 8046597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of three fluoroquinolones on QT interval in healthy adults after single doses.
    Noel GJ; Natarajan J; Chien S; Hunt TL; Goodman DB; Abels R
    Clin Pharmacol Ther; 2003 Apr; 73(4):292-303. PubMed ID: 12709719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis.
    Tankovic J; Bachoual R; Ouabdesselam S; Boudjadja A; Soussy CJ
    J Antimicrob Chemother; 1999 May; 43 Suppl B():19-23. PubMed ID: 10382871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
    Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
    Bauernfeind A
    J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT; Blondeau JM
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
    Saravolatz L; Manzor O; Check C; Pawlak J; Belian B
    J Antimicrob Chemother; 2001 Jun; 47(6):875-7. PubMed ID: 11389122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus.
    Blondeau JM; Borsos S; Hesje CK
    J Chemother; 2007 Apr; 19(2):146-51. PubMed ID: 17434822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model.
    Gillespie SH; Morrissey I; Everett D
    J Med Microbiol; 2001 Jun; 50(6):565-570. PubMed ID: 11393294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae.
    Lemmen SW; Häfner H; Klik S; Lütticken R; Zolldann D
    Chemotherapy; 2003 May; 49(1-2):33-5. PubMed ID: 12714807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin.
    Firsov AA; Zinner SH; Vostrov SN; Portnoy YA; Lubenko IY
    J Antimicrob Chemother; 2002 Oct; 50(4):533-9. PubMed ID: 12356798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of five fluoroquinolones by Mycobacterium tuberculosis H37Rv.
    Piddock LJ; Ricci V
    J Antimicrob Chemother; 2001 Dec; 48(6):787-91. PubMed ID: 11733462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.